

March 2019

Philip C. Hoffman, M.D.

The University of Chicago
Section of Hematology/Oncology
Department of Medicine
5841 S. Maryland Avenue, MC 2115
Chicago, IL 60637
Office: (773)-702-6109
Fax: (773)-702-0963
Email: phoffman@medicine.bsd.uchicago.edu
Web page: <http://www.uchospitals.edu/physicians/philip-hoffman.html>

ACADEMIC APPOINTMENTS

1980-87	Assistant Professor, Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois
1987-89	Associate Professor of Clinical Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois
1989-95	Associate Professor of Medicine, Section of Hematology/ Oncology, The University of Chicago, Chicago, Illinois
1995-2003	Professor of Clinical Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois
2003 -	Professor of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois

Ph.D.-Granting Committee, Program, Institute, and Center Appointments

1980-	Member, University of Chicago Comprehensive Cancer Center
-------	---

ACADEMIC TRAINING

1970	B.S., Pennsylvania State University, University Park, Pennsylvania (as part of Pennsylvania State University-Jefferson Medical College Five-Year Cooperative Program in Medicine)
1972	M.D., Jefferson Medical College of Thomas Jefferson University (now Sidney Kimmel Medical College of TJU), Philadelphia, Pennsylvania
1972-73	Medical Intern, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

- 1973-75 Medical Resident, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
- 1977-80 Fellow, Hematology/Oncology, Department of Medicine, The University of Chicago Hospitals and Clinics, Chicago, Illinois

LICENSING AND BOARD CERTIFICATION

- 1975 American Board of Internal Medicine (lifetime certification)
- 1980 Hematology Subspecialty, American Board of Internal Medicine (lifetime certification)
- 1981 Medical Oncology Subspecialty, American Board of Internal Medicine (lifetime certification)
- 1977- Medical License #036-054578, Illinois

POSITIONS HELD

- 1975-77 Medical Epidemiologist, Epidemic Intelligence Service, Hospital Infections Branch, Bureau of Epidemiology, Center for Disease Control, U.S. Public Health Service, Atlanta, Georgia
- 1985-89 Adjunct Attending Physician, Michael Reese Medical Center
- 1987-2000 Consulting Attending Physician, Louis A. Weiss Memorial Hospital, Chicago, Illinois
- 1999-2018 Consulting Medical Staff, Little Company of Mary Hospital, Evergreen Park, IL
- 2008- Associate Section Chief for Appointments and Promotions, Section of Hematology/Oncology, Department of Medicine, The University of Chicago

PROFESSIONAL SOCIETIES

- 1979- Member, American College of Physicians
- 1983- Member, American Society of Clinical Oncology
- 1986- Member, American Society of Hematology

HONORS, PRIZES, AND AWARDS

- 1970 B.S. with Highest Distinction, Pennsylvania State University
- 1970 Microbiology Prize, Jefferson Medical College
- 1971 Alpha Omega Alpha Honor Society, Jefferson Medical College

1972	M.D., Magna Cum Laude, Jefferson Medical College
1972	C.V. Mosby Book Award, Jefferson Medical College
1983-86	Junior Faculty Clinical Fellowship, American Cancer Society
1983-91, 1993, 1994 1996-99, 2006, 2007, 2009-2017	Faculty honoree, Senior Class composite portrait, Pritzker School of Medicine
1992, 1993, 2000, 2001, 2006 2007, 2009, 2011, 2013	Faculty honoree, Internal Medicine Residency Graduating Class, University of Chicago Department of Medicine
2006 -	Master, Academy of Distinguished Medical Educators, Pritzker School of Medicine, The University of Chicago
2009, 2015	Preclinical Teacher of the Year Award, Department of Medicine, The University of Chicago
2012	Postgraduate Teaching Award, Department of Medicine, The University of Chicago
2012-	Senior Faculty Scholar, Bucksbaum Institute for Clinical Excellence
2013	Clinical Teacher of the Year Award, Department of Medicine, The University of Chicago
2015	Preclinical Teacher of the Year Award, Department of Medicine, The University of Chicago
2016	Excellence in Teaching Award, American Society of Clinical Oncology
2016	Faculty Physician Peer Role Model Award, Pritzker School of Medicine
2017	Laurence Baker Lectureship in Medical Education, University of Michigan, Section of Hematology/Oncology

CLINICAL

I am a hematologist/oncologist who is primarily a clinician, with particular interest in breast cancer and lung cancer.

1980-	Inpatient Hematology/Oncology Service and Hematology/Oncology Consultation Service, 2-3 months per year
1980-	Outpatient Hematology/Oncology Clinics (three half-days per week)

- 1987-2018 Outpatient clinic at Weiss Memorial Hospital (1987-2000) or Little Company of Mary Hospital (2000-present): one half day per week
- 1980- Attending physician, multidisciplinary thoracic oncology conference (1-2 hours per week)
- 1985- Attending physician, multidisciplinary breast oncology conference (1-2 hours per week)

SCHOLARSHIP

Peer-reviewed publications in the primary literature, exclusive of abstracts:

1. **Hoffman PC**, Arnow PA, Goldmann DA, et al.: False-positive blood cultures. Association with non-sterile blood collection tubes. *JAMA* 236: 2073-2075, 1976.
2. **Hoffman PC**, Fraser DW and Hinson PL: Delayed hypersensitivity reactions in patients with *Mycobacterium chelonae* and *Mycobacterium fortuitum* infections. *Am. Rev. Resp. Dis.* 117: 527-531, 1978.
3. Edwards KE, Allen JR, Miller MJ, Yogev R, **Hoffman PC**, Klotz R, Marubio S, Burkholder E, Williams T and Davis AT: Enterobacter aerogenes primary bacteremia in pediatric patients. *Pediatrics* 62: 304-306, 1978.
4. DeMeester TR, Golomb HM, Kirchner P, Rezai-Zadeh K, Streeter DL, **Hoffman PC** and Cooper M: The role of Gallium-67 scanning in the clinical staging and preoperative evaluation of patients with carcinoma of the lung. *Ann. Thorac. Surg.* 28: 451-464, 1979.
5. **Hoffman PC**, Golomb HM, Bitran JD, et al.: Small cell carcinoma of the lung. A five-year experience with combined modality therapy. *Cancer* 46: 2550-2556, 1980.
6. **Hoffman PC**, Richman CM, Hsu RC, Chung J, Scanu AM and Yachnin S: Effect of oxygenated sterol compounds on human bone marrow granulocytic progenitor cells. *Blood* 57: 164-169, 1981.
7. **Hoffman PC**, Fraser DW, Robicsek F, et al.: Two outbreaks of sternal wound infections due to the Mycobacterium fortuitum complex. *J. Infect. Dis.* 143: 533-542, 1981.
8. Richman CM, Kinnealey AE and **Hoffman PC**: Granulopoietic effects of lithium on human bone marrow in vitro. *Exp. Hematol.* 9: 449-455, 1981.
9. Newman SB, Bitran JD, Golomb HM, **Hoffman PC**, DeMeester TR and Raghavan V: VP16-213 in combined modality treatment of small cell carcinoma of the lung. *Eur. J. Cancer Clin. Oncol.* 18: 343-346, 1982.
10. **Hoffman PC**, Richman CM, Larson RA, Yachnin S: Cholesterol and mevalonic acid are independent requirements for the in vitro proliferation of human bone marrow granulocyte progenitor cells (CFU-C): Studies using ML-236B. *Blood* 61: 667-671, 1983.
11. **Hoffman PC**, Newman SB, Golomb HM, DeMeester TR, Blough RR, and Sovik CA: Metastatic non-small cell bronchogenic carcinoma: A randomized trial of sequential vs. combination chemotherapy. *Eur. J. Cancer Clin. Oncol.* 19: 33-38, 1983.

12. Newman SB, Bitran JD, **Hoffman PC**, Raghavan V, DeMeester TR, Golomb HM: Lack of efficacy of vinblastine and cisplatin in patients with progressive small cell carcinoma of the lung. *Cancer Treat. Rep.* 67: 831-832, 1983.
13. Newman SB, DeMeester TR, Golomb HM, **Hoffman PC**, Little AG, Raghavan V: Treatment of modified Stage II (T1N1MO, T2N1MO) non-small cell bronchogenic carcinoma. *J. Thorac. Cardiovasc. Surg.* 86: 180-185, 1983.
14. Albain KS, Bitran JD, Golomb HM, **Hoffman PC**, DeMeester TR, Skosey C, Noble S, Blough RR: Trial of vindesine, etoposide, and cisplatin in patients with previously treated, advanced-stage, non-small cell bronchogenic carcinoma. *Cancer Treat. Rep.* 68: 413-415, 1984.
15. Little AG, Ferguson MK, DeMeester TR, **Hoffman PC**, Skinner DB: Esophageal carcinoma with respiratory tract fistula. *Cancer* 53: 1322-1328, 1984.
16. Madej PJ, Bitran JD, Golomb HM, **Hoffman PC**, DeMeester T, Desser RK, Karl R, Raghavan V, Newman SB, Skosey C: Combined modality, therapy for Stage III MO non-small cell lung cancer. A five-year experience. *Cancer* 54: 5-12, 1984.
17. Shepard KV, Golomb HM, Bitran JD, **Hoffman PC**, Skinner SB, DeMeester TR, Skosey C: CAMP chemotherapy for metastatic non-oat cell bronchogenic carcinoma: A seven-year experience (1975-1981) for 160 patients. *Cancer* 56: 1618-1623, 1985.
18. Albain KS, True LD, Golomb HM, **Hoffman PC**, Little AG: Large cell carcinoma of the lung. Ultrastructural differentiation and clinicopathologic correlations. *Cancer* 56: 1618-1623, 1985.
19. Bitran JD, Golomb HM, **Hoffman PC**, Albain KS, Evans R, Little AG, Purl S, Skosey C: Protochemotherapy in non-small cell lung carcinoma: An attempt to increase surgical resectability and survival. A preliminary report. *Cancer* 57: 44-53, 1986.
20. Albain KS, **Hoffman PC**, Bitran JD, Golomb HM, DeMeester TR, Little AG, Raghavan VT, Griem ML, Blough RR, Skosey C: Pleural involvement in Stage III MO non-small cell bronchogenic carcinoma: A need to differentiate subtypes. *Am. J. Clin. Oncol.* 9: 255-261, 1986.
21. Ferguson MK, Little AG, Golomb HM, **Hoffman PC**, DeMeester TR, Beveridge R, Skinner DB: The role of adjuvant therapy following resection of T1N1MO and T2N1MO non-small cell lung cancer. *J. Thorac. Cardiovasc. Surg.* 91: 344-349, 1986.
22. Ferguson MK, MacMahon H, Little AG, Golomb HM, **Hoffman PC**, Skinner DB: The regional accuracy of computed tomography of the mediastinum in lung cancer staging. *J. Thorac. Cardiovasc. Surg.* 91: 498-504, 1986.
23. Jacobs RH, Greenburg A, Bitran JD, **Hoffman PC**, Albain KS, Desser RK, Potkul L, Golomb HM: A ten year experience with combined modality therapy for Stage III small cell lung carcinoma. *Cancer* 58: 2177-2184, 1986.
24. Hatfield MK, MacMahon H, Ryan JW, Little AG, **Hoffman PC**, Ferguson MK, DeMeester TR, Golomb HM: Postoperative recurrence of lung cancer: Detection by whole body gallium scintigraphy. *AJR* 147: 911-916, 1986.
25. Little AG, Ferguson MK, Golomb HM, **Hoffman PC**, Vogelzang NJ, Skinner DB: Pleuroperitoneal

- shunting for malignant pleural effusions. *Cancer* 58: 2740-2743, 1986.
26. Jacobs RH, Bitran JD, Deutsch M, **Hoffman PC**, Sinkule J, Purl S, Golomb HM: Phase II Study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma. *Cancer Treat. Rep.* 71: 311-312, 1987
 27. Jacobs RH, Awan A, Bitran JD, **Hoffman PC**, Little AG, Ferguson MK, Weichselbaum RR, Golomb HM: An undefined role for prophylactic cranial irradiation in adenocarcinoma of the lung. *Cancer* 59: 2016-2019, 1987.
 28. Ratain MJ, Kaminer LS, Bitran JD, Larson RA, LeBeau MM, Skosey C, Purl S, **Hoffman PC**, Wade J, Vardiman JW, Daly K, Rowley JD, Golomb HM: Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small cell carcinoma of the lung. *Blood* 70: 1412-1417, 1987.
 29. Naunheim KS, Taylor JR, Skosey C, **Hoffman PC**, Ferguson MR, Golomb HM, Little AG: Adenosquamous lung carcinoma: Clinical characteristics, treatment, and prognosis. *Ann. Thorac. Surg.* 44: 462-466, 1987.
 30. Robicsek F, **Hoffman PC**, Masters TN, Daugherty HK, Cook JW, Selle JG, Mauney CU, Hinson P: Rapidly Growing Nontuberculous Mycobacteria: A New Enemy of the Cardiac Surgeon. *Ann Thorac Surg* 46: 703-710, 1988.
 31. Williams SF, Bitran JD, **Hoffman PC**, Robin E, Fullem L, Beschorner J, Golic J, Golomb HM: High-Dose, Multiple-Alkylator Chemotherapy with Autologous Bone Marrow Reinfusion in Patients with Advanced Non-Small Cell Lung Cancer. *Cancer* 63: 238-242, 1989.
 32. Vokes EE, Bitran JD, **Hoffman PC**, Ferguson MK, Weichselbaum RR, Golomb HM: Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. *Chest* 96: 110-113, 1989.
 33. MacMahon H, Scott W, Ryan JW, Montner SM, Little AG, **Hoffman PC**, Ferguson MK, Golomb HM: Efficacy of computed tomography of the thorax and upper abdomen and whole-body gallium scintigraphy for staging of lung cancer. *Cancer* 64: 1404-1408, 1989.
 34. Porile JL, Olopade OI and **Hoffman PC**: Gastric adenocarcinoma presenting with soft tissue masses. *Am. J Gastro.* 85: 76-77, 1990.
 35. Ferguson MK, Skosey C, **Hoffman P**, Golomb H: Sex-associated differences in presentation and survival in patients with lung cancer. *Am J Gastroenterol*, 85: 1402-1407, 1990.
 36. Vokes EE, Vijayakumar S, **Hoffman PC**, Ferguson MK, Bitran JD, Krishasamy S, Jacobs R, Golomb HM: 5-Fluorouracil with oral leucovorin, hydroxyurea, and concomitant radiotherapy for Stage III non-small cell lung cancer. *Cancer*, 66: 437-442, 1990.
 37. Vokes EE, Vijayakumar S, Bitran JD, **Hoffman PC**, Golomb HM: Role of systemic therapy in advanced non-small cell lung cancer. *Am. J. Med.* 89: 777-786, 1990.
 38. Olopade OI, Larson RA, Mick R, Watson SM, **Hoffman PC**, Ultmann JE, Golomb HM: Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. *Leukemia* 4: 127-131, 1990.

39. Bitran JD, Vokes EE, **Hoffman PC**, Ellis E, Gradishar W, English C, Golomb HM: Combined modality therapy for stage III non-small cell lung cancer: The University of Chicago experience. In: Proceedings of the Third International Conference on Neoadjuvant Chemotherapy. Ed: P. Banzet, J.F. Holland, D. Khayat, M. Weil, Springer-Verlag, 1991, pp 427-431.
40. Gradishar WJ, Mick R, **Hoffman PC**, Bitran JD, Krishnasamy S, Ferguson MK, Golomb HM: The impact on survival by adjuvant chemotherapy and radiation therapy in Stage II non-small cell lung cancer. *Am. J. Clin. Oncol*, 15: 405-411, 1992.
41. Vokes EE, Haraf DJ, **Hoffman PC**: Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: A phase I study. *Cancer Chemother Pharmacol* 33: 203-9, 1993.
42. Fleming GF, Ratain MJ, O'Brien SM, Schilsky RL, **Hoffman PC**, Richards JM, Vogelzang, NJ, Kasunic DA and Earhart RH: Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. *J. Nat. Can. Inst.* 86: 368-372, 1994.
43. Drinkard LC, Haraf DJ, **Hoffman PC**, Golomb HM, Ferguson MK, Vogelzang NJ, Vokes EE: Concomitant chemoradiotherapy with cisplatin dose escalation as palliative therapy for advanced malignancies of the chest. In: Cancer Treatment Update. Ed: P Banzet, J.F. Holland, D. Khayat, M. Weil, Springer-Verlag, 1994, pp 370-374.
44. **Hoffman PC**, Ferguson MK, Haraf DJ, Drinkard LC, Golomb HM, Vokes EE: Induction chemotherapy, surgery and concomitant chemoradiotherapy for carcinoma of the esophagus. In: Cancer Treatment Update. Ed: P. Banzet, J.F. Holland, D. Khayat, M. Weil, Springer-Verlag, 1994, pp 386-388.
45. Vokes EE, Haraf DJ, **Hoffman PC**, Bitran JD, Ferguson MK, Golomb HM: Concomitant chemoradiotherapy for non-small cell lung cancer. *Lung Cancer* 10 (Suppl 1): S253-S261, 1994.
46. Gradishar WJ, Haraf DJ, **Hoffman PC**, Rademaker AW, Ferguson MK, Golomb H, Bitran JD, Vokes EE: A phase II trial of neoadjuvant chemotherapy and concomitant chemoradiotherapy for the treatment of locally advanced non-small cell lung cancer. *Oncology Reports* 1: 957-962, 1994.
47. Vokes EE, Drinkard LC, Samuels BL, **Hoffman PC**, Watson S, Bitran JD, Haraf JD, Ferguson MK, Golomb HM: A Phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine, (Navelbine) for advanced non-small cell lung cancer: Rationale and study design. *Semin Oncol* 21 (Suppl 10): 79-84, 1994.
48. Ferguson MK, Reeder LB, **Hoffman PC**, Haraf DJ, Drinkard LC, Vokes EE: Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. *Ann. Surg. Oncol.* 2: 101-106, 1995.
49. Vokes EE, Haraf DJ, Drinkard LC, **Hoffman PC**, Ferguson MK, Vogelzang NJ, Watson S, Lane NJ, Golomb HM: A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. *Cancer Chemother Pharmacol* 35: 304-312, 1995.
50. **Hoffman PC**, Krauss SA, Drinkard LC, Masters GA, Samuels BL, Bitran JD, Golomb HM, Watson S, Vokes EE: Paclitaxel and ifosfamide: A Multicenter Phase I study in advanced non-small cell lung cancer. *Semin Oncol* 22 (Suppl 9): 38-41, 1995.

51. Masters GA, Drinkard LC, **Hoffman PC**, Lane N, Watson S, Samuels BL, Bitran JD, Golomb HM, Vokes EE: A phase I -phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. *Cancer J Sci Am* 1:288-294, 1995.
52. Drinkard LC, **Hoffman PC**, Samuels BL, Watson S, Bitran JD, Golomb HM, Vokes EE: Dose-intensification—A phase I study of ifosfamide with vinorelbine (Navelbine): rationale and study design in non-small cell lung cancer. *Semin Oncol* 22 (2 Suppl 5): 30-37, 1995.
53. **Hoffman PC**, Masters GA, Drinkard LC, Krauss SA, Samuels BL, Golomb HM, Vokes EE: Ifosfamide plus paclitaxel in advanced non-small-cell lung cancer: A phase I study. *Ann Oncol* 7: 314-316, 1996.
54. **Hoffman PC**, Masters GA, Drinkard LC, Krauss SA, Samuels BL, Golomb HM, Vokes EE: Ifosfamide-based combination chemotherapy in advanced non-small cell lung cancer: Two phase I studies. *Semin Oncol* 23 (3 Suppl 6): 11-15, 1996.
55. Masters GA, **Hoffman PC**, Drinkard LC, Watson S, Samuels BL, Golomb HM, Vokes EE: Preliminary report on a phase I study of ifosfamide and vinorelbine (Navelbine) in advanced non-small cell lung cancer. *Semin Oncol* 23 (2 Suppl 5): 11-18, 1996.
56. Vokes EE, Haraf DJ, Masters GA, **Hoffman PC**, Drinkard LC, Ferguson M, Olak J, Watson S, Golomb HM: Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: A phase I study. *Semin Oncol* 23 (2 Suppl 5): 48-52, 1996.
57. Vokes EE, **Hoffman PC**, Masters GA, Golomb HM, Drinkard LC, Krauss SA: Ifosfamide-based chemotherapy for non-small cell lung cancer: phase I/II studies at the University of Chicago. *Semin Oncol* 23 (3 Suppl 7): 15-18, 1996.
58. Masters GA, **Hoffman PC**, Hsieh A, Drinkard LC, Mick R, Samuels BL, Guaspari A, Golomb HM, Vokes EE: Phase I study of vinorelbine and ifosfamide in advanced non-small cell lung cancer. *J Clin Oncol* 15: 884-892, 1997.
59. Vokes EE, Masters GA, Mauer A, Haraf DJ, **Hoffman PC**, Golomb HM: Clinical studies of docetaxel (Taxotere) and concomitant chest therapy. *Semin Oncol* 24(Suppl 14): S15-26-S15-29, 1997.
60. Vokes EE, Mauer AM, **Hoffman PC**, Masters GA, Watson S, Golomb HM: Paclitaxel/carboplatin plus ifosfamide in non-small cell lung cancer. *Semin Oncol* 24 (4 Suppl 12):S12-67-S12-69, 1997.
61. Fleming GF, O'Brien SM, **Hoffman PC**, Vokes EE, Vogelzang NJ, Schilsky RL, Waggoner SE, Ratain MJ: Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. *Cancer Chemother Pharmacol* 39: 227-232, 1997.
62. Mauer AM, Masters GA, Haraf DJ, **Hoffman PC**, Watson SM, Golomb HM, Vokes EE: Phase I study of docetaxel with concomitant thoracic radiation therapy. *J Clin Oncol* 16:159-164, 1998.
63. Vokes EE, Masters GA, Mauer AM, **Hoffman PC**, Watson S, Golomb HM: Ifosfamide-based three-drug combination regimens in non-small cell lung cancer. *Semin Oncol* 25(1 Suppl 2):19-22, 1998.

64. **Hoffman PC**, Haraf DJ, Ferguson MK, Drinkard LC, Vokes EE: Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: A long-term analysis. *Ann Oncol* 9:647-651, 1998.
65. Masters GA, Mauer AM, **Hoffman PC**, Wyka D, Samuels BL, Krauss SA, Watson S, Golomb H, Vokes EE: A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small cell lung cancer. *Ann Oncol* 9:677-680, 1998.
66. Vokes EE, Mauer AM, **Hoffman PC**, Haraf DJ: Combined modality therapy in non-small cell lung and esophageal cancer: A phase I dose-escalated study of docetaxel with concurrent radiotherapy. *Semin Oncol* 25 (3 Suppl 8):28-32, 1998.
67. Masters GA, Haraf DJ, **Hoffman PC**, Drinkard LC, Krauss SA, Ferguson MK, Olak J, Samuels BL, Golomb HM, Vokes EE: Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. *J Clin Oncol* 16:2157-2163, 1998.
68. Fleming GF, Kugler JW, **Hoffman PC**, Ansari R, Bitran JD, Klepsch A, Malone D, Fasanmade AA, Ratain MJ, Vokes EE: Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. *J Clin Oncol* 16:2032-2037, 1998.
69. Masters GA, **Hoffman PC**, Drinkard LC, Samuels BL, Golomb HM, Vokes EE: A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung. *Semin Oncol* 25 (1 Suppl 2):8-14, 1998.
70. Vokes EE, Ansari, RH, Masters, GA, **Hoffman PC**, Klepsch A, Ratain MJ, Sciortino DF, Lad TE, Krauss S, Fishkin PAS, Golomb HM: A phase II study of 9-aminocamptothecin in advanced non-small cell lung cancer. *Ann Oncol* 9:1085-1090, 1998.
71. Stadler WM, Vogelzang NJ, **Hoffman PC**, Arrietta R, Masters G, Fishkin P, Gibbons J, Lad TE, Vokes EE: CI-980 in Renal Cell and Non-Small Cell Lung Cancer. *Cancer Therapeutics* 1:318-320, 1998.
72. Zent CS, Ratajczak MZ, Anastasi J, **Hoffman PC**, Gewirtz AM: Relationship between megakaryocyte mass and serum thrombopoietin levels as revealed by a case of cyclic megakaryocytic thrombocytopenic purpura. *Br. J. Haematol* 105:452-458, 1999.
73. Shammo JM, Calhoun B, Mauer AM, **Hoffman PC**, Baron JM, Baron BW: First two cases of immune hemolytic anemia associated with ceftizoxime. *Transfusion* 39:838-844, 1999.
74. Ferguson MK, Wang J, **Hoffman PC**, Haraf, DJ, Olak J, Masters GA, Vokes EE: Sex-associated differences in survival of patients undergoing resection for lung cancer. *Ann Thorac Surg* 69:245-50, 2000.
75. Vokes EE, Gordon GS, Mauer AM, Rudin CM, Krauss SA, Szeto L, Golomb HM, **Hoffman PC**: A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non-small-cell lung cancer. *Clinical Lung Cancer* 2:128-132, 2000.
76. Vokes EE, Gordon GS, Rudin CM, Mauer AM, Watson S, Krauss S, Arrieta R, Golomb HM, **Hoffman PC**: A phase II trial of 9-aminocamptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. *Invest New Drugs* 19:329-33, 2001.

77. George CM, Haraf DJ, Mauer AM, Krauss SA, **Hoffman PC**, Rudin CM, Szeto L, Vokes EE: A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. *Invest New Drugs* 19:303-10, 2001.
78. **Hoffman PC**, Cohen EE, Masters GA, Haraf DJ, Mauer AM, Rudin CM, Krauss SA, Huo D, Vokes EE: Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. *Lung Cancer* Oct;38(1):65-71, 2002.
79. Vokes EE, Charoentum C, Gordon GS, Rudin CM, Krauss SA, **Hoffman PC**, Mauer AM, Lee S, Watson S. Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer. *Clin Lung Cancer*. 2002 May; 3(4):265-70.
80. Mauer AM, Ansari RH, **Hoffman PC**, Krauss SA, Taber D, Tembe SA, Gabrys GT, Cotter T, Schumm LP, Szeto L, Vokes EE. Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer. *Ann Oncol*. 2003 May;14(5):722-8.
81. Winegarden JD, Mauer AM, Gajewski TF, **Hoffman PC**, Krauss S, Rudin CM, Vokes EE. A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer. *Lung Cancer*. 2003 Feb;39(2):191-6.
82. Baron BW, van Besien K, **Hoffman PC**, Kohn OF, Rossof AH, Baron JM. Thrombotic thrombocytopenic purpura after cephalosporin administration: a possible relationship. *Transfusion*. 2003 Sep;43(9):1317-21.
83. Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, **Hoffman PC**, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC Jr, Tezcan H, Waples J, Ward J, Yee LK. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. *Cancer*. 2004 Feb;15;100(4):859-68.
84. Rudin CM, Kozloff M, **Hoffman PC**, Edelman MJ, Karnauskas R, Tomek R, Szeto L, Vokes EE. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. *J Clin. Oncol*. 2004 Mar 15;22(6):1110-7.
85. Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, **Hoffman PC**, Vokes EE. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. *Ann Oncol*. 2004 June;15(6):915-20.
86. Choong NW, Mauer AM, **Hoffman PC**, Rudin CM, Winegarden JD, Villano JL, Kozloff M, Wade JL 3rd, Sciortino DF, Szeto L, Vokes EE. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. *J Thorac Oncol* 2006 Mar; 1(3): 245-51.
87. Seiwert, TY, Connell PP, Mauer AM, **Hoffman PC**, George CM, Szeto L, Salgia R, Posther KE,

Nguyen B, Haraf DJ, Vokes EE: A phase I study of pemetrexed, carboplatin and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. *Clin Cancer Res* 2007 Jan 15; 13(2): 515-22

88. Shaikh AY, Haraf DJ, Salama JK, Salgia R, **Hoffman PC**, Ferguson MK, Connell PP. Chemotherapy and High Dose Radiotherapy Followed by Resection for Locally Advanced Nonsmall Cell Lung Cancers. *Am J Clin Oncol* 30(3):258-63, 2007.
89. Choong NW, **Vokes EE**, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, **Hoffman PC**, Krauss SA, Szeto L, **Mauer AM**. Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-Small Cell Lung Cancer. *J Thorac Oncol* 3(1):59-67, 2008.
90. Choong NW, Mauer AM, Haraf DJ, Lester E, **Hoffman PC**, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE. Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer. *J Thorac Oncol* 3(9):1003-11, 2008.
91. Miller AA, Wang XF, Gu L, **Hoffman P**, Khatri J, Dunphy F, Edelman MJ, Bolger M, Vokes EE, Green MR: Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). *J Thorac Oncol* 3(10):1159-65, 2008
92. Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, **Hoffman PC**, Szeto L, Vokes EE Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. *Med Oncol*. 2010 Aug 21. [Epub ahead of print]
93. Shumway D, Corbin K, Salgia R, **Hoffman P**, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. *Lung Cancer*. 2011 Dec;74(3):446-50. Epub 2011 Jun 14.
94. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, **Hoffman PC**, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. *Cancer*. 2012 Jun 1;118(11):2962-70. doi: 10.1002/cncr.26611. Epub 2011 Oct 21.
95. Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, **Hoffman P**, Ballas MS, Liu SV, Gandara DR. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. *J Thorac Oncol*. 2012 Mar;7(3):574-8.
96. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, **Hoffman PC**, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. *J Thorac Oncol*. 2012 Feb;7(2):376-81.

97. Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, **Hoffman PC**, Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic breast cancer. *Breast Cancer Res Treat.* 2012 Jan 13. [Epub ahead of print]
98. Lukas RV, Nicholas MK, Villaflor V, **Hoffman PC**, Salgia R: Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. *J Neurol Res.* 2012 Feb 1;2(1):1-9.
99. Maitland ML, Levine MR, Lacouture ME, Wroblewski, KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, **Hoffman PC**, Salgia R, Carbone DP, Karrison TG, Vokes EE: Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. *BMC Cancer.* 2014 Jan 4; 14:5
100. Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crino L, Tsai CM, Kim JH, Cho EK, **Hoffman PC**, Orlov SV, Serwatowski P, Wang J, Floley MA, Horan JD, Shepherd FA: Adjuvant erlotinib versus placebo in patients with stage IB-IIIa non-small cell lung cancer (RADIANT): A randomized, double-blind, phase III trial. *J Clin Oncol* 2015 Dec 1; 33(34): 4007-14.
101. Vigneswaran J, Tan YC, Murgu SD, Won BM, Patton KA, Villaflor VM, **Hoffman PC**, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R: Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institution investigation. *Oncotarget* 2016 Feb 26
102. Nanda R, Stringer-Reasor EM, Saha P, Kocherginsky M, Gibson J, Libao B, Hoffman PC, Obeid E, Merkel DE, Khrantsova G, Skor M, Krausz T, Cohen RN, Ratain MJ, Fleming GF, Conzen SD: A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. *Springerplus.* 2016; 5(1): 947.

Reviews, Commentaries, and Editorials:

1. **Hoffman PC** and Dixon RE: Control of influenza in the hospital. *Ann. Intern. Med.* 87: 725-728, 1977.
2. **Hoffman PC**, Bitran JD, Golomb HM: Chemotherapy of metastatic non-small cell bronchogenic carcinoma. *Semin. Oncol.* 10: 112-123, 1983.
3. **Hoffman PC**, Albain KS, Bitran JD, Golomb HM: Current concepts in small cell carcinoma of the lung. *Ca* 34: 269-281, 1984.
4. **Hoffman PC**: Idiopathic thrombocytopenic purpura in pregnancy. *Clin. Perinatol.* 12: 599-605, 1985.
5. Vokes EE, Vijayakumar S, Bitran JD, **Hoffman PC**, Golomb HM: Role of systemic therapy in advanced non-small-cell lung cancer. *Am. J. Med.* 89: 777-786, 1990.

6. **Hoffman PC**, Mauer AM, Vokes EE: Lung Cancer [Seminars Series]. *Lancet* 355: 479-85, 2000
7. **Hoffman PC**: Immune hemolytic anemia—selected topics. *Hematology Am Soc Hematol Educ Program*, 2006, 13-18.
8. **Hoffman PC**: Immune hemolytic anemia--selected topics. *Hematology Am Soc Hematol Educ Program*. 2009:80-6. Review
9. Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, **Hoffman P**, Villafior V, and Vokes EE. Personalized Treatment of Lung Cancer. *Seminars in Oncology* 38: 274-283, 2011.

Book chapters:

1. **Hoffman PC**. Chemotherapy of carcinoma of the esophagus. In: Carcinoma of the Esophagus, eds. Levin B and DeMeester TR. New York: Grune and Stratton, 1985, p. 259-270.
2. **Hoffman PC** and Ultmann JE. Clinical Evaluation: Non-invasive methods. In: Clinical Evaluation of Antitumor Therapy, eds. Muggia FM and Rozenzweig M Boston: Martinus Nijhoff Publishers, 1987, p. 55-83.
3. **Hoffman PC**: The role of surgical resection in the management of small cell carcinoma of the lung. In: Lung Cancer: A Comprehensive Text Book, eds. Bitran JD, Golomb HM, Little AG, Weichselbaum RR. New York: Grune and Stratton, 1988, p. 359-368.
4. Morrow M, **Hoffman PC**, Weichselbaum RR: Management of locally advanced breast cancer. In: Breast Diseases, 2nd ed., eds. Harris J, Hellman S, Henderson IC, Kinne D. Philadelphia, J.B. Lippincott Company, 1991, p. 767-774.
5. **Hoffman PC**: Specific sites of metastatic disease and emergencies: Gastrointestinal and hepatic metastases. In: Breast Diseases, 2nd ed., eds. Harris J, Hellman S, Henderson IC, Kinne D. Philadelphia, J.B. Lippincott Company, 1991, p. 745-750.
6. Bitran JD, Vokes EE, **Hoffman PC**, Ellis E, Gradishar W, English C, and Golomb HM: Combined modality therapy for stage III non-small cell lung cancer: The University of Chicago Experience. In: Neo-Adjuvant Chemotherapy. Ed: Banzet P, Holland JF, Khayat D, Weil M, Springer-Verlag, Paris, France, 427-431, 1991.
7. Bitran JD, Vokes EE, **Hoffman PC**, Gradishar W, English C, Golomb HM: Neoadjuvant therapy for stage III non-small-cell lung cancer: A review. In: Lung Cancer Differentiation: Implications for diagnosis and treatment. Ed: Bernal SE, Hesketh PJ. New York, Marcel Dekker, Inc., 1992, p. 293-304.
8. Ferguson MK, Albertucci M, Lackner RP, **Hoffman PC**, Golomb HM. Patterns of presentation of carcinoma of the esophagus and cardia in patients less than 50 years old. *Proc. of the Fifth World Congress of the ISDE, Kyoto, Japan, August 1992.*
9. Mitchell RB, **Hoffman PC**: Anemia, Leukopenia, and Elevated Blood Counts. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care. New York, McGraw-Hill, Inc., 1992, p. 1807-1817.

10. Gradishar WJ, **Hoffman PC**: The Oncologic Emergencies. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care. New York, McGraw-Hill, Inc., 1992, p. 1847-1863.
11. Mauer AM, Hoffman PC, Masters GA, Golomb HM, Vokes EE: Combinations of paclitaxel and ifosfamide in non-small cell lung cancer. In: Johnson DH, Klastersky J, eds. Taxanes in Lung cancer. New York: Marcel Dekker, 1998, p. 171-179.
12. Mitchell RB, **Hoffman PC**: Anemia, Leukopenia, and Elevated Blood Counts. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care, 2nd ed. New York, McGraw-Hill, Inc., 1998, p. 1033-1042.
13. Gradishar WJ, **Hoffman PC**: The Oncologic Emergencies. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care, 2nd ed. New York, McGraw-Hill, Inc., 1998, p. 1075-1090.
14. **Hoffman PC**: A 64-year-old woman with dyspnea and radicular leg pain after receiving chemotherapy for breast cancer [review of meningeal carcinomatosis]. In: Sahn SA, Heffner JE, eds. Critical Care Pearls, 2nd ed. Philadelphia, Hanley & Belfus, 1998, p. 461-463.
15. Lamont EB, **Hoffman PC**: The diagnosis and management of oncologic emergencies. In: Oncologic Therapies, eds. Vokes EE, Golomb HM. Berlin, Springer-Verlag, 1999, p.211-227.
16. Lamont EB, **Hoffman PC**: Oncologic Emergencies. In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical Care, 3rd ed. New York, McGraw-Hill, Inc., 2005, p. 1099-1110.

Clinical trials completed (recent)

- RADIANT: A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Single Agent Tarceva (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients with Stage IB-III A Non Small Cell Lung Carcinoma who have EGFR-Positive Tumors (Institutional PI)
- H3E-MC-JMIG: Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology (Institutional PI)
- E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (>4 cm) -IIA Non-Small Cell Lung Cancer (NSCLC). (Institutional PI)
- SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy + Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer With Recurrence Score of 25 or Less (Institutional PI)

INVITED SPEAKING

- 1999 Lecture tour on advanced lung cancer: Sydney, Melbourne, Brisbane, Australia
- 2002 “Clinical Vignettes”, presented at the Second International Chicago Symposium on Malignancies of the Chest and Head & Neck, Chicago, IL, October 2002
- 2003 “Lung Cancer in the Elderly”, presented at University of Chicago-sponsored program, Cancer in the Elderly. Chicago, IL, October 18, 2003
- 2004 “Update on Lung Cancer”, presented at State of the Art Course, American Thoracic Society, Washington, DC, March 2004
- 2004 “Clinical Vignettes”, presented at the Third International Chicago Symposium on Malignancies of the Chest and Head & Neck, Chicago, IL, October 2004
- 2005 “Update on Lung Cancer”, presented at State of the Art Course, American Thoracic Society, Chicago, IL, March 2005
- 2006 Moderator, Fellows’ Symposium, Fourth International Chicago Symposium on Malignancies of the Chest and Head & Neck, Chicago, IL, October 2006
- 2006 Speaker, “Immune Hemolytic Anemias”: Education Program of the American Society of Hematology Annual Meeting, Orlando, FL, December 2006
- 2009 Speaker, “Immune Hemolytic Anemias”: Education Program of the American Society of Hematology Annual Meeting, New Orleans, LA, December 2009
- 2011 Speaker, “Doctor, is there any hope?” Clinical Problems in Oncology Session, American Society of Clinical Oncology Annual Meeting
- 1995- Resident and fellow education sessions, Sections of Thoracic Surgery, Surgical Oncology, Pulmonary Medicine—various updates and reviews on breast cancer, lung cancer, 3-4 hours per year
- 2016 Tumor Board Presentation. Multidisciplinary Symposium in Thoracic Oncology, International Association for the Study of Lung Cancer (IASLC), Chicago, Illinois September 2016
- 2018 BRAF-positive non-small cell lung cancer. Chicago Lung Cancer Updates 2018, October 2018

INVITED, ELECTED, OR APPOINTED EXTRAMURAL SERVICE

- 1987-2003 Member, Cancer Control Science Committee, Cancer and Leukemia Group B (CALGB)

1990-1995	Committee on Cancer Prevention and Control, American Society of Clinical Oncology
2008-2011	Member, CME Subcommittee, Cancer Education Committee, American Society of Clinical Oncology
2017-	Member, Oncology Drugs Advisory Committee, U.S. Food and Drug Administration (anticipate Chair position, July 2019)

TEACHING

For Pritzker School of Medicine (M.D.):

(a) Didactic

1980-	Coordinator and major lecturer, Hematology/Oncology lectures for third-year Medicine students on Medicine rotation (2 hours per quarter)
1980-1988	Attending preceptor, Physical Diagnosis Course, seven of nine years
1981-	Coordinator and principal lecturer, Hematology Section, Clinical Pathophysiology and Therapeutics Course, second-year medical students (5 full days every year)
1982-1988	Lecturer, Clinical Orientation Program, first-year medical students (one session per year)
1992-2000	Lecturer, Introduction to Clinical Medicine Course, first-year medical students (one session per year)
1982-2002	Lecturer, Topics in Hematology Course (senior student elective) (one session per year)
1995-	Lecturer, Anticoagulation topics, Medicine 777 (Advanced Clinical Pharmacology), fourth-year medical students (2 hours per year)
2007-	Lecturer, hemostasis and thrombosis unit, Vignettes in Physiology Course, fourth-year medical students (four hours per year)
2005-	Lecturer, Disorders of Coagulation and Introduction to Transfusion Practices, Third-year medical students on Internal Medicine Clerkship (2 hours per quarter)

(b) Clinical

1980-	Daily rounding including 1-2 medical students during 2-3 months per year on service
-------	---

For Graduate medical education (residency and clinical fellowships):

(a) Didactic

- 1981- Attending physician, Residents' Morning Report, Department of Medicine, one hour every month
- 1980- Medical Residents' Board Review Course, Oncology and Hematology Sections (2-3 hours per year)
- 1980- Hematology/Oncology Fellows lecture series (2-3 hours per year)
- 1985- Hematology/Oncology Fellows Board Review series and Journal Club (2-3 hours per year)

(b) Clinical

- 1980- Daily rounding including 2 residents during 2-3 months per year on service
- 1980- Preceptor teaching in outpatient clinics, 3-4 fellows per year
- 2012, 2013 Poster Competition Judge, American College of Physicians, Northern Illinois Chapter, Associates Meeting
- 2015-2018 Poster Competition Judge, Internal Medicine Residency Research Day, Department of Medicine, University of Chicago

For Continuing medical education:

- 1981- Speaker and Tumor Board Consultant, multiple outside hospital CME programs (formerly coordinator of Tumor Board, St. Joseph Medical Center, South Bend, IN)—Holy Cross Hospital, Chicago, IL; South Suburban Hospital, Hazel Crest, IL; Palos Community Hospital, Palos Heights, IL; Little Company of Mary Hospital, Evergreen Park, IL; St. Catherine Hospital, East Chicago, IN;
- 1984-95 Lecturer, Annual or biennial Medical Knowledge Self-Assessment Program Review Course, American College of Physicians (coordinator for Hematology/Oncology, 1985-88)
- 1991, 1993, 1995, 1997 Lecturer, Medical Oncology Board Review Course, National Center for Advanced Medical Education (formerly Cook County Graduate School of Medicine)
- 1994, 1996 Lecturer, Hematology Board Review Course, National Center for Advanced Medical Education (formerly Cook County Graduate School of Medicine)
- 1999 Lecturer, Midwest Clinical Conference, Chicago Medical Society
- 2012, 2013, 2015, 2016 "Effective Lecturing", Faculty Advancing in Medical Education (FAME) Program, Pritzker School of Medicine and NorthShore University Health System

Other:

1981-1992	Lecturer, American Cancer Society Tumor Registrars' Training Course (1-2 hours per year)
1998-2002	Lecturer, University of Chicago "Mini-Med School" (2 hours per year)
Various	Speaker, Y-Me National Breast Cancer Organization meetings

SERVICE

University of Chicago

Committee membership:

1983-1993	Internship Selection Committee, Department of Medicine
1983-	Physical Therapy Advisory Committee (later Therapy Services Advisory Committee)
1983-1984	<i>Ad hoc</i> Committee on Residency Training (E. Page, chair), Department of Medicine
1984-1988	Housestaff Evaluation Committee, Department of Medicine
1986	<i>Ad hoc</i> Committee on Senior Year Curriculum (F.Coe, chair), Department of Medicine
1987-	Member, Physician Credentials and Privileges Subcommittee, Medical Staff Organization, University of Chicago Medical Center
1988-1993	Ambulatory Care Education Committee, Department of Medicine (H. Humphrey, Chair)
1988-1997	Chairman, Home Health Care Research Committee
1988-2002	Member, University of Chicago Hospitals Home Care Physician Advisory Board
1989-2003	Alpha Omega Alpha Advisory Committee, Pritzker School of Medicine
1999-	Member, Medical Liability Committee, University of Chicago Hospitals
2001-2004, 2009-2013	Member, Committee on Appointments and Promotions, Biological Sciences Division, The University of Chicago
2003-7	Compliance Advisory Committee, University of Chicago Biological Sciences Division Practice Plan
2004-6	Member, Professional Liability Risk Reduction Subcommittee, University of Chicago Biological Sciences Division Practice Plan

2010- Committee on Professionalism, Medical Staff Organization, The University of Chicago Medicine & Biological Sciences

Leadership:

1990-1996 Chair, Curriculum Committee, Pritzker School of Medicine

2000-2003 Chair, Physician Credentials and Privileges Subcommittee, Medical Staff Organization, University of Chicago Medical Center

2003- Chair, Medical Liability Committee, University of Chicago Hospitals

Other:

1982-2002 Medical Director, Medical Oncology Inpatient Unit, The University of Chicago Medical Center

1984-2013 Co-Director, Physician-Directed Outpatient Practice in Hematology/Oncology

1987-2004 Internal Medicine Internship and Residency Advisor for Senior Medical Students, Department of Medicine, University of Chicago

1987-1992 Coordinator, Quality Assurance activities, Section of Hematology/Oncology

Extramural

REVIEWER FOR JOURNALS

Archives of Internal Medicine

Cancer

JAMA

Journal of Clinical Oncology

Lancet